Stat3-driven cancer-related inflammation as a key therapeutic target for cancer immunotherapy

Immunotherapy

Volumn 3, Issue 5, 2011, Pages 587-590

  Kato, Takuma ^a  

^a MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

cancer immunotherapy; cancer related inflammation; NF kB; STAT3; tumor microenvironment

Indexed keywords

CANCER VACCINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; STAT3 PROTEIN; TUMOR ANTIGEN;

ADAPTIVE IMMUNITY; ADOPTIVE IMMUNOTHERAPY; ANGIOGENESIS; CANCER IMMUNOTHERAPY; CANCER RISK; CARCINOGENESIS; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; GENE MUTATION; GENE TARGETING; GENETIC ENGINEERING; HUMAN; IMMUNOREGULATION; IMMUNOSURVEILLANCE; INFLAMMATION; INNATE IMMUNITY; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT;

CYTOKINES; HUMANS; IMMUNOTHERAPY; INFLAMMATION; NEOPLASMS; STAT3 TRANSCRIPTION FACTOR;

EID: 79955907823     PISSN: 1750743X     EISSN: None     Source Type: Journal    
DOI: 10.2217/imt.11.26     Document Type: Review

References (20)

1. Dunn GP, Bruce AT, Ikeda H et al.: Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 3, 991-998 (2002). (Pubitemid 35363648)
2. Balkwill F, Mantovani A: Inflammation and cancer: back to Virchow? Lancet 357, 539-545 (2001).
3. Allavena P, Garlanda C, Borrello MG et al.: Pathways connecting inflammation and cancer. Curr. Opin. Gene. Dev. 18, 3-10 (2008). (Pubitemid 351694444)
4. Jacobs EJ, Thun MJ, Bain EB et al.: A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence. J. Natl Cancer Inst. 99, 608-615 (2007). (Pubitemid 47073542)
5. Mantovani A: Cancer: inflaming metastasis. Nature 457, 36-37 (2009).
6. Nickoloff BJ, Ben-Neriah Y, Pikarsky E: Inflammation and cancer: is the link as simple as we think? J. Invest. Dermatol. 124, X-XIV (2005).
7. DeNardo DG, Andreu PCoussens LM: Interactions between lymphocytes and myeloid cells regulate pro- versus anti-tumor immunity. Cancer Metastasis Rev. 29, 309-316 (2010).
8. Yu H, Pardoll DJove R: STATs in cancer inflammation and immunity: a leading role for STAT3. Nat. Rev. Cancer 9, 798-809 (2009).
9. Kortylewski M, Yu H: Role of Stat3 in suppressing anti-tumor immunity. Curr. Opin. Immunol. 20, 228-233 (2008).
10. Lee H, Herrmann A, Deng JH et al.: Persistently activated Stat3 maintains constitutive NF-kB activity in tumors. Cancer Cell 15, 283-293 (2009).
11. Grivennikov SI, Karin M: Dangerous liaisons: STAT3 and NF-kB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev. 21, 11-19 (2010).
12. Kortylewski M, Kujawski M, Wang T et al.: Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat. Med. 11, 1314-1321 (2005). (Pubitemid 41752912)
13. Kortylewski M, Xin H, Kujawski M et al.: Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment. Cancer Cell 15, 114-123 (2009).
14. Chiarle R, Simmons WJ, Cai H et al.: Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target. Nat. Med. 11, 623-629 (2005). (Pubitemid 40868302)
15. Ling X, Arlinghaus RB: Knockdown of STAT3 expression by RNA interference inhibits the induction of breast tumors in immunocompetent mice. Cancer Res. 65, 2532-2536 (2005). (Pubitemid 40490046)
16. Verma NK, Dourlat J, Davies AM et al.: STAT3-stathmin interactions control microtubule dynamics in migrating T-cells. J. Biol. Chem. 284, 12349-12362 (2009).
17. Goodman WA, Young AB, McCormick TS et al.: Stat3 Phosphorylation mediates resistance of primary human T cells to regulatory T cell suppression. J. Immunol. 186(6), 3336-3345 (2011).
18. Musteanu M, Blaas L, Mair M et al.: Stat3 is a negative regulator of intestinal tumor progression in Apc(Min) mice. Gastroenterology 138, 1003-1011 E1-E5 (2010).
19. Herrmann A, Kortylewski M, Kujawski M et al.: Targeting Stat3 in the myeloid compartment drastically improves the in vivo antitumor functions of adoptively transferred T cells. Cancer Res. 70, 7455-7464 (2010).
20. Juliano R, Alam MR, Dixit V et al.: Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides. Nucleic Acids Res. 36, 4158-4171 (2008). (Pubitemid 351984831)